<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044382</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MDS-501-001</org_study_id>
    <nct_id>NCT00044382</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience
      erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>25</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-5013</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration.

          -  Baseline mean hemoglobin &lt; 10.0 g/dL (untransfused) and/or be transfusion dependent
             defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline.

          -  More than 30 days must have elapsed since any previous treatment for MDS, other than
             transfusion.

          -  Women must not be pregnant or lactating

          -  No use of another experimental study drug within 30 dy\ays of baseline

          -  Understand and sign written informed consent

          -  Able to adhere to study visit schedule, understand and comply with other protocol
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2002</study_first_submitted>
  <study_first_submitted_qc>August 28, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2002</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Deborah Ingenito</name_title>
    <organization>Celgene Corporation</organization>
  </responsible_party>
  <keyword>Revimid</keyword>
  <keyword>CC5013</keyword>
  <keyword>CC-5013</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

